Background Effective decongestion is a key therapeutic goal during hospitalisation for acute heart failure (HF), but the ...

For more than two decades, the crucial dilemma of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has remained unchanged: the same therapies used to treat myocardial ...

Background Nationwide studies report the high incidence of major health outcomes following myocardial infarction (MI). This ...

Background Obesity is a major contributor to cardiovascular disease (CVD). Different fat depots may have distinct effects on ...

Endocrine Clinic, and Department of Cardiology, Royal Infirmary, Edinburgh, UK Dr A D Toft, Endocrine Clinic, Royal Infirmary, Edinburgh EH3 9YW, UK If you wish to reuse any or all of this article ...

In the early 2000s, the natural history of heart failure (HF) was vividly illustrated, highlighting a defining feature of HF progression: a prolonged course of fluctuating yet steadily worsening ...

Background Proteomic biomarkers have shown promise in predicting various cardiovascular conditions, but their utility in assessing the risk of atrial fibrillation (AF) remains unclear. This study ...

Correspondence to Dr Niket Patel, Cardiology Department, Royal Free Hospital, Pond Street, London NW3 2QG, UK; niketpatel{at}nhs.net To understand the evolution in the strategies for the treatment of ...

7 WA Centre for Rural Health, University of Western Australia, Perth, Australia Correspondence to Karice K Hyun, The George Institute for Global Health, Sydney Medical School, University of Sydney, ...

Objective Cardiac amyloidosis (CA) is a rapidly progressive disease that portends poor prognosis. Our objective was to evaluate the prognostic impact of relative regional strain ratio (RRSR, a measure ...

Prevention of stroke and systemic thromboembolism remains the cornerstone for management of atrial fibrillation (AF) and flutter. Multiple risk assessment models for stroke and systemic ...